US-based biotechnology company Seismic Therapeutic has dosed the initial cohort of healthy participants in a randomised Phase ...

Seismic Therapeutic, Inc., the machine learning immunology company, today announced the dosing of the first healthy subject cohort in a Phase 1 clinical trial of S?1117, a novel engineered Fc-fused ...

Biohaven stock tumbled for the second day running Tuesday after its bipolar mania treatment failed in a three-week study.

Cancer therapy has advanced with molecularly targeted approaches and immunotherapy, yet chemotherapy remains essential for ...

Biohaven (BHVN) highlighted the success of BHV-1300, its potential first-in-class IgG selective degrader, in achieving rapid and deep ...

Biohaven Ltd. (NYSE: BHVN) ("Biohaven"), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range ...

Takeda has returned to BridGene Biosciences for another small-molecule collaboration—this time focused on immunology as well as neurology. BridGene’s pursuit of undruggable targets is enabled ...

A Zimbabwean delegation led by Martin Muduva from the Zimbabwe Human Rights Commission (ZHRC) poses for a photo with Uganda's Deputy IGG Anne Twinomugisha Muhairwe and the IGG technical team at ...